FP7H2020HORIZON
Robert Bosch Gesellschaft fur Medizinische Forschung mbH
- Country
- DEGermany
- Defence projects
- 0
- Projects, all programmes
- 11
- As coordinator
- 1
- EU contribution (CORDIS)
- EUR 6,969,137
- Active
- 2008 to 2024
Projects
11 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| NEMESISNovel Effect biomarkers for MEtabolic disruptorS: evidence on health Impacts to answer science and policy needS | HORIZON | 2024 | Participant | EUR 654,213 |
| MOBILISE-DConnecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement | H2020 | 2019 | Participant | EUR 2,432,796 |
| PreventITEarly risk detection and prevention in ageing people by self-administered ICT-supported assessment and a behavioural change intervention delivered by use of smartphones and smartwatches | H2020 | 2016 | Participant | EUR 665,325 |
| U-PGxUbiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen | H2020 | 2016 | Participant | EUR 561,394 |
| DEFENSINACTIVITYThe influence of environmental factors on antimicrobial activity of human intestinal defensins | FP7 | 2013 | Participant | EUR 366,519 |
| FARSEEINGFAll Repository for the design of Smart and sElf-adaptive Environments prolonging INdependent livinG | FP7 | 2012 | Participant | EUR 532,357 |
| PREDECTNew Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours | FP7 | 2011 | Participant | EUR 339,864 |
| ANTIRESDEVThe effects of antibiotic administration on the emergence and persistence of antibiotic-resistant bacteria in humans and on the composition of the indigenous microbiotas at various body sites | FP7 | 2009 | Participant | EUR 59,871 |
| FIGHTINGDRUGFAILUREPriorities and Standards in Pharmacogenomic Research: Opportunities for a Safer and More Efficient Pharmacotherapy | FP7 | 2009 | Coordinator | EUR 1,270,261 |
| NEUROSISEfficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia | FP7 | 2009 | Participant | EUR 86,537 |
| KINACEPTNovel anti-inflammatory compounds for autoimmune diseases | FP7 | 2008 | Participant | Not stated |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.